Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury

In brief

The purpose of the present research study is to investigate for the first time, the safety and tolerability of infusion doses of AP214 in subjects having heart surgery such as coronary bypass graft and/or valve repair or replacement surgery. AP214, the investigational drug, is being developed to potentially prevent post-surgical kidney injury after thoracic aortic aneurysm repair.

Key facts

Study ID

NCT00628264

Run by

Action Pharma A/S

People needed

75

Starts

2008-03-01

Expected to finish

2009-06-01

Last updated by the study team

2009-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has signed the trial specific informed consent form.
• Patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized e.g., tubal occlusion, hysterectomy, bilateral salpingectomy), regardless of ethnicity.
• Patients undergoing CABG, valve(s), CABG/valve and/or aortic root or ascending aortic aneurysm repair surgery.
• Cleveland Clinic Renal Score ≥ 2 (higher than average risk for AKI).
• EF ≥ 30%, evaluated within 2 months prior to screening visit.

You may not qualify if…

• Cardiac surgery to be performed "off pump" without cardiopulmonary bypass.
• Circulatory arrest in connection with aortic root or ascending aortic aneurysm repair surgery.
• Confirmed or suspected endocarditis.
• Requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure.
• Receiving Aprotinin during the trial, from Screening to Day 90.
• Having undergone cardiovascular catheterization ≤ 48 hours prior to scheduled surgery.
• Active peptic ulcer disease and gastritis.
• Hemoccult positive stools, hematological, bleeding, and coagulation disorders.
• Receiving dopamine at renal doses (2-4 mcg/kg/min), from Screening to Day 90.
• S-Creatinine greater than 2.1 mg/dl.
• Known or suspected hypersensitivity to the investigational medicinal product.
• Known or suspected hypersensitivity to ondansetron or other selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.
• Current participation in any other interventional clinical trial.
• Previously dosed with AP214.
• Use of investigational medicinal products within the previous 6 months.
• Body weight above 140 kg.
• History of any organ transplant.
• Women who are of childbearing potential, pregnant or breast-feeding.
• Current abuse of alcohol or substance, according to the investigator's medical judgment
• Has a mental incapacity or language barriers precluding adequate understanding of trial procedures.
• Is considered by the Investigator unsuitable to participate in the trial for any other reason for instance due to a significant serious underlying condition

Where it is running

• Shands Hospital at Alachua General Hospital — Gainesville, Florida, United States
• Shands Hopsital at University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.